EcoDrugPlus

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSPKIG00000014030
Gene Symbol: FGFR3
3 Cross references
193 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSPKIG00000008367
Gene Symbol: FLT3
2 Cross references
133 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSPKIG00000008011
Gene Symbol: FLT4
3 Cross references
193 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSPKIG00000023233
Gene Symbol: FOLH1B
3 Cross references
340 Possible Orthologues:

Folate Receptor

Ensembl ID : ENSPKIG00000022982
Gene Symbol: FOLR
1 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSPKIG00000005845
Gene Symbol: FSHR
1 Cross references
200 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSPKIG00000018922
Gene Symbol: FRK
3 Cross references
216 Possible Orthologues:

Galactosidase, Alpha

Ensembl ID : ENSPKIG00000021176
Gene Symbol: GLA
1 Cross references
196 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSPKIG00000001252
Gene Symbol: LOC111837022
2 Cross references
159 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSPKIG00000013923
Gene Symbol: LOC111833688
2 Cross references
153 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1

Ensembl ID : ENSPKIG00000001161
Gene Symbol: LOC111833418
4 Cross references
130 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-6-Like

Ensembl ID : ENSPKIG00000000804
Gene Symbol: LOC111849392
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).